MTHFR C677T基因多态性、血浆HCY水平与精神分裂症患者心血管风险的相关性

来源期刊：广州医药 | 109-112 发布时间：2021-11-28 收稿时间：2025/11/13 17:59:54 阅读量：27

作者：: 谢育坤,

宁婷,

徐鹏,

吴向红,

郭耀光,

郑艳辉,

王阳顺,

关键词：: 精神分裂症 MTHFR C677T多态性同型半胱氨酸心血管疾病

DOI：: 10.3969/j.issn.1000-8535.2020.01.025

收稿时间：: 2019-10-12
修订日期：
接收日期：
引用总数：: 0

目的探讨精神分裂症患者亚甲基四氢叶酸还原酶 (MTHFR)基因多态性、血浆HCY水平与心血管疾病发生风险的相关性。方法收集住院精神分裂症患者164例,记录一般资料和测定患者MTHFR C677T基因多态性、血浆同型半胱氨酸(HCY)水平、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、Framingham心血管疾病发生风险评分(FRS)等指标。其中10年心血管疾病发生风险用 Framingham心血管疾病风险评分表来计算。结果 1.CC、CT、TT基因型血浆HCY水平呈增高趋势,差异有统计学意义(P<0.001);CC基因型和CT基因型血浆HCY水平与FRS评分呈正相关关系(r_s=0.27,P=0.016;r_s=0.42,P=0.002);TT基因型血浆HCY水平与FRS评分之间无相关性(r_s=0.05,P=0.784)。2.低、中、高风险组的血浆HCY水平差异无统计学意义;低风险组和中风险组血浆HCY水平与FRS评分呈正相关关系(r_s=0.29,P=0.000;r_s=0.55,P=0.006);高风险组血浆HCY水平与FRS评分无相关性(r_s=-0.16,P=0.66)。结论精神分裂症病人血浆HCY水平与FRS评分具有相关性,MTHFR C677T基因多态性、血浆HCY水平是对精神分裂症病人心血管疾病风险评估的合理补充之一。

1、 van W R, RUTTEN B P, PEERBOOMS O, et al. MTHFR and risk of metabolic syndrome in patients with schizophrenia[J]. Schizophr Res, 2010,121(1-3):193-198.

2、 OSBORN D P, SARAH H, OMAR R Z, et al. Cardiovascular risk prediction models for people with severe mental illness: results from the prediction and management of cardiovascular risk in people with severe mental illnesses (PRIMROSE) research program[J]. JAMA Psychiatry, 2015,72(2):143-151.

3、 FENG L G, SONG Z W, XIN F, et al. Association of plasma homocysteine and methylenetetrahydrofolate reductase C677T gene variant with schizophrenia: a chinese han population-based case-control study[J]. Psychiatry Res, 2009,168(3):205-208.

4、赵帅, 周晓琴, 夏海龙,等. 住院精神分裂症患者心血管疾病发生风险研究[J]. 中国神经精神疾病杂志,2017,43(9):539-543.

5、 TAY Y H, NURJONO M, LEE J. Increased Framingham 10-year CVD risk in Chinese patients with schizophrenia[J]. Schizophr Res, 2013,147(1):187-192.

6、 de H M, SCHREURS V, VANCAMPFORT D, et al. Metabolic syndrome in people with schizophrenia: a review[J]. World Psychiatry, 2009,8(1):15-22.

7、 CORRELL C U, FREDERICKSON A M, KANE J M, et al. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics[J]. Bipolar Disord, 2008,10(7):788-797.

8、 FRCP R H, FRCPSYCH R P D. Diabetes and cardiovascular risk in severe mental illness: a missed opportunity and challenge for the future[J]. Pract Diab, 2011,27(2):79-84.

9、 TIIHONEN J, LONNQVIST J, WAHLBECK K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)[J]. Lancet, 2009,374(9690):620-627.

10、 TURNER T H. Long term outcome of treating schizophrenia[J]. BMJ, 2004,329(7474):1058-1059.

11、王国强. 《全国精神卫生工作规划(2015-2020年)》解读[J]. 中国实用乡村医生杂志,2016,10(1):43-46.

12、中国高血压防治指南修订委员会. 中国高血压防治指南(2018年修订版)[J]. 中国心血管杂志,2019,19(1):6-49.

13、中华医学会精神病学分会. 中国精神障碍分类与诊断标准第三版(精神障碍分类)[J]. 中华精神科杂志,2001,34(3):184-188.

14、李建平, 卢新政, 霍勇,等. H型高血压诊断与治疗专家共识[J]. 中华高血压杂志,2016,8(3):243-248.

15、 SIAW-CHEOK L, ESHA DAS G. Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: epidemiology, metabolism and the associated diseases[J]. Eur J Med Genet, 2015,58(1):1-10.

16、易峰, 毛静宇, 张洋洋,等. 精神分裂症患者血浆同型半胱氨酸水平的Meta分析[J]. 中国神经精神疾病杂志,2013,39(8):463-468.

17、杨东英, 陆小兵, 李佑辉,等. 亚甲基四氢叶酸还原酶基因多态性和血浆同型半胱氨酸水平与首发精神分裂症的关系[J]. 中华行为医学与脑科学杂志,2007,16(10):901-902.

18、 D'AGOSTINO R B, VASAN R S, PENCINA M J, et al. General cardiovascular risk profile for use in primary care: the framingham heart study[J]. Circulation, 2008,117:743-753.

19、 FOGUET-BOREU Q, FERNANDEZ SAN MARTIN M I, FLORES MATEO G, et al. Cardiovascular risk assessment in patients with a severe mental illness: a systematic review and meta-analysis[J]. BMC Psychiatry, 2016,16:141.

20、 de HERT M, CORRELL C U, BOBES J, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care[J]. World Psychiatry, 2011,10(1):52-77.

21、 ANDREASSEN O A, DJUROVIC S, THOMPSON W K, et al. Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors[J]. Am J Hum Genet, 2013,92(2):197-209.